Speakers

Expand/Collapse

Stefanie Krumm, PhD
Associate Director, Infectious Disease Vaccines
BioNTech

Day Two

Thursday, May 20 2021

11:15 am | Development of Synthetic mRNA-based Vaccines Against Infectious Diseases Pathogens

Andreas Kuhn, PhD
Sr. VP, RNA Biochemistry & Manufacturing
BioNTech

Day One

Wednesday, May 19 2021

11:15 am | Vaccine Leader’s Panel Discussion: Optimising Next-Generation Vaccine Development, Lessons Learned From the Pandemic, and Future Outlook

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

10:00 am | Development of an mRNA-based COVID-19 Vaccine at ‘lightspeed’: From Pre-Clinical Studies to Large-scale Manufacture

Philip Dormitzer, PhD
Vice President & Chief Scientific Officer: Viral Vaccines
Pfizer

Day One

Wednesday, May 19 2021

11:15 am | Vaccine Leader’s Panel Discussion: Optimising Next-Generation Vaccine Development, Lessons Learned From the Pandemic, and Future Outlook

Johan Vekemans, PhD
Global Clinical Head, SARS-CoV-2 Vaccine
AstraZeneca

Day One

Wednesday, May 19 2021

11:15 am | Vaccine Leader’s Panel Discussion: Optimising Next-Generation Vaccine Development, Lessons Learned From the Pandemic, and Future Outlook

Ali Fattom, PhD
Chief Scientific Officer
Blue Willow Biologics

Day One

Wednesday, May 19 2021

3:30 pm | Alternative Route of Vaccine Administration to Confer Nasal Immunity

Stefan Mueller, PhD
COVID-19 Program Lead & Vice President Pre-Clinical Development
CureVac

Lidia Oostvogels, PhD
VP Area Head Infectious Diseases
CureVac

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

12:30 pm | CVnCov: CureVac’s mRNA-based Vaccine Candidate Against COVID-19

Jesse Erasmus, PhD
Director of Virology
HDT Bio

Day Two

Thursday, May 20 2021

3:00 pm | Replicating RNA as a Platform for Active or Passive Immunization Against Emerging Infectious Diseases

Norman Begg, PhD
Former Chief Medical Officer
GSK Vaccines

Day One

Wednesday, May 19 2021

11:15 am | Vaccine Leader’s Panel Discussion: Optimising Next-Generation Vaccine Development, Lessons Learned From the Pandemic, and Future Outlook

9:00 am | Overview of Today’s Vaccine Market Highlighting Significant Investments, Partnerships, and Opportunities

Jean Boyer, PhD
VP Analytical Science
Inovio

Day Two

Thursday, May 20 2021

9:00 am | Powering a New Decade of DNA-based Vaccines with Optimized Plasmid Design and Delivery

Kate Broderick, PhD
Sr. VP, R&D
Inovio

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

12:00 pm | INO-4800 – A DNA based Vaccine Against COVID-19

Jason DeHart, PhD
Senior Principal Scientist, RNA & Targeted Therapeutics
Janssen

Day Two

Thursday, May 20 2021

2:00 pm | Development of a Self-replicating RNA Platform for Prophylactic and Therapeutic Vaccines

Luis Brito, PhD
Senior Director, Formulation Science
Moderna

Day Two

Thursday, May 20 2021

11:45 am | Optimization of Lipid Nanoparticles for the Delivery of mRNA Vaccines

Jacqueline Miller, MD
Sr. VP Therapeutic Area Head, Infectious Diseases
Moderna

Day One

Wednesday, May 19 2021

11:15 am | Vaccine Leader’s Panel Discussion: Optimising Next-Generation Vaccine Development, Lessons Learned From the Pandemic, and Future Outlook

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

10:30 am | Moderna’s COVID-19 Vaccine: A Summary of Available Clinical Data

Dong Yu
Pre-clinical R&D
GSK Vaccines

Day One

Wednesday, May 19 2021

10:00 am | Development of a Potent Zika Virus Vaccine Using Selfamplifying RNA

Jakob Cramer, PhD
Head of Clinical Development
CEPI

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

11:30 am | Clinical and Operational Challenges of COVID-19 Vaccine Development and Future Opportunities

Larry Corey, PhD
President & Director Emeritus
Fred Hutchinson Cancer Research Center

Luk Vandenberghe, PhD
Director
Grousbeck Gene Therapy Center

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

2:30 pm | Development of AAVCOVID: A Single Dose AAV-based Vaccine for COVID-19

Galit Alter, PhD
Professor of Medicine
Harvard Medical School

Day One

Wednesday, May 19 2021

9:30 am | Systems Serology to Define Correlates of Immunity to SARSCoV- 2

Amesh Adalja, PhD
Senior Scholar
John Hopkins Centre for Health Security

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

3:00 pm | A Framework to Analyse the Pandemic Potential of Pathogens: COVID-19 and Future Directions

Ronit Satchi-Fainaro, PhD
Head, Cancer Research and Nanomedicine Laboratory
Tel Aviv University

Day Two

Thursday, May 20 2021

2:30 pm | Novel Approaches to Delivering miRNA and siRNAs to Endothelial Cells: From Cancer Immunotherapy to COVID-19 Vaccine

Ami Patel, PhD
Research Assistant Professor
The WISTAR Institute

Day Two

Thursday, May 20 2021

9:30 am | Optimizing DNA Vaccines Against Emerging Infectious Diseases

Mohadeseh Hasanpourghadi, PhD
Post Doctoral Fellow
The WISTAR Institute

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

2:00 pm | Immunogenicity of Chimpanzee Adenovirus Vector Vaccines Expressing SARS-CoV2 Spike and Nucleocapsid

Hildegund Ertl, PhD
Professor
The WISTAR Institute

Day One

Wednesday, May 19 2021

2:30 pm | Immunogenicity and Efficacy of Chimpanzee Adenovirus Vectors in a SIV-challenge Nonhuman Primate Model

Matthias Schnell, PhD
Professor & Chair, SKMC Microbiology & Immunology
Thomas Jefferson University

Day One

Wednesday, May 19 2021

12:15 pm | Rabies Virus-based Vaccine Platforms Against Emerging Infectious Diseases

Stanley Plotkin, PhD
Professor Emeritus of Virology
University of Pensylvania

Pre-Conference Symposium: SARS-CoV-2

Tuesday, May 18 2021

9:30 am | Controlled Human Infection Models to Further Validate the Efficacy of COVID-19 Vaccines

Louis Picker, PhD
Associate Director & Professor
Vaccine and Gene Therapy Institute, OHSU

Day One

Wednesday, May 19 2021

4:00 pm | Programming Cellular Immunity with Cytomegalovirus (CMV) Vaccine Vectors

Dan Barouch , PhD., MD.,
William Bosworth Castle Professor of Medicine
Harvard Medical School

Day One

Wednesday, May 19 2021

2:00 pm | Development of an Ad26/Env Mosaic HIV Vaccine

Susanne Rauch
Principal Scientist
CureVac

Day Two

Thursday, May 20 2021

10:45 am | An Optimized mRNA Vaccine Platform: Broad Application Against Various Viruses